Ceritinib is a Small Molecule owned by Novartis, and is involved in 37 clinical trials, of which 28 were completed, and 9 are ongoing.

Ceritinib acts as an ALK inhibitor. A kinase inhibitor works by temporarily blocking the lock, so that the key can not fit and a certain concentration of kinase inhibitors has to be reached in order to block the signal from being passed sufficiently in order to stop the kinase from regulating the expression of certain genes. LDK-375 combats ALK based tumors, which are designed to interfere with (or inhibit) ALK’s signaling pathway (either by stopping ALK from passing a signal or stopping another kinase in the pathway from passing its signal).

The revenue for Ceritinib is expected to reach a total of $155m through 2027. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ceritinib NPV Report.

Ceritinib is originated and owned by Novartis.

Ceritinib Overview

Ceritinib (Zykadia/ LDK378), is an antineoplastic agent. It is formulated as hard capsules, film coated tablets for oral route of administration. Zykadia is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Zykadia indicated as a first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.

It was also under development for colorectal cancer, adenocarcinoma, cholangiocarcinoma, pancreatic cancer, hepatocellular cancer, gastric cancer or esophageal adenocarcinoma, recurrent glioblastoma multiforme, anaplastic large cell lymphoma and Inflammatory myofibroblastic tumor, melanoma, metastatic or locally advanced anaplastic/undifferentiated thyroid cancer, head and neck cancer, hematological malignancy.

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – Ceritinib

Report Segments
  • Innovator (NME)
Drug Name
  • Ceritinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Non Malignant Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.